Wuhan Healthgen Biotechnology (SHSE:688765) Construction In Progress: ¥993.71 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
19 GF Score
Price ¥55.00
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology Construction In Progress?

Wuhan Healthgen Biotechnology SHSE:688765 +5.40% 19 Construction In Progress is ¥993.71 Mil as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

Wuhan Healthgen Biotechnology's quarterly construction in progress increased from Sep. 2025 (¥364.73 Mil) to Dec. 2025 (¥602.79 Mil) and increased from Dec. 2025 (¥602.79 Mil) to Mar. 2026 (¥993.71 Mil).

Wuhan Healthgen Biotechnology's annual construction in progress increased from Dec. 2023 (¥9.72 Mil) to Dec. 2024 (¥133.76 Mil) and increased from Dec. 2024 (¥133.76 Mil) to Dec. 2025 (¥602.79 Mil).

Wuhan Healthgen Biotechnology Construction In Progress Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology Construction In Progress Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 200.05 409.30 9.72 133.76 602.79

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 245.22 364.73 602.79 993.71
SHSE:688765
19GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of ¥993.71 Mil mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a Construction In Progress of ¥993.71 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Wuhan Healthgen Biotechnology and its competitors.
Is Wuhan Healthgen Biotechnology's Construction In Progress too high?
Wuhan Healthgen Biotechnology's current Construction In Progress is ¥993.71 Mil. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Construction In Progress compare to ZTS and UTHR?
Wuhan Healthgen Biotechnology's Construction In Progress of ¥993.71 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Wuhan Healthgen Biotechnology and its competitors. Wuhan Healthgen Biotechnology's current Construction In Progress is ¥993.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Construction In Progress of ¥993.71 Mil. The current Construction In Progress is ¥993.71 Mil. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Construction In Progress is ¥993.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
19GF Score

Get the complete analysis for SHSE:688765

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥55.00
Price